Giant Cell Arteritis Indication Strategy Report 2026: IL-6, JAK1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

ANCA-Associated Vasculitis Indication Strategy Report 2026: C5aR1, CD20, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Minimal Change Disease Indication Strategy Report 2026: CD80, IL-13, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Membranous Nephropathy Indication Strategy Report 2026: PLA2R, CD20, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

IgA Nephropathy Indication Strategy Report 2026: APRIL, BAFF, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Warm AIHA Indication Strategy Report 2026: FcRn, CD20, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Immune Thrombocytopenia Indication Strategy Report 2026: TPO-R, SYK, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

CIDP Indication Strategy Report 2026: FcRn, CD20, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

NMOSD Indication Strategy Report 2026: AQP4, C5, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Multiple Sclerosis Indication Strategy Report 2026: CD20, S1PR1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Myasthenia Gravis Indication Strategy Report 2026: FcRn, C5, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Celiac Disease Indication Strategy Report 2026: TGM2, IL-15, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.